Haemonetics Corp $HAE

Recent News (7)

• Argo Biopharma to Present Positive Phase II Updated Results of siRNA Therapeutic BW-20805 for HAE at Bradykinin Symposium 2026 PR Newswire · 04 Sep 2026 - Oral Presentation in Session VI: Hereditary Angioedema SHANGHAI and NEW YORK, Sept. 4, 2026 /PRNewswire/ -- Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA …
• Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026 GlobeNewswire · 03 Sep 2026 ZUG, Switzerland, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs o…
• Dėl AB „Ignitis gamyba“ teikiamų paslaugų reguliavimo GlobeNewswire · 27 Aug 2026 AB „Ignitis grupė“ (toliau – Grupė) informuoja, kad 2026 m. rugpjūčio 27 d. Valstybinė energetikos reguliavimo taryba (toliau – VERT) priėmė nutarimą (nuoroda), kuriuo pratęsė AB „Ignitis gamyba“ Kruo…
• BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan GlobeNewswire · 25 Aug 2026 — Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to <12 years in Japan —
• Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update GlobeNewswire · 12 Aug 2026 ZUG, Switzerland, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet n…
• BTIG raises Haemonetics stock price target to $96 on strong results Investing.com · 06 Aug 2026 BTIG raises Haemonetics stock price target to $96 on strong results
• Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema GlobeNewswire · 22 Jul 2026 ZUG, Switzerland, July 22, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet n…